Back

GenFleet Therapeutics says GFH375-cetuximab program slated for China breakthrough designation

Verifying
  • GenFleet Therapeutics disclosed GFH375-cetuximab’s pending breakthrough designation review in China.
  • Shares closed at HK$29.46, up 13.75%, with 37.47 million shares traded.
  • The application was filed August 13, 2026, with public comments ending September 24.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.